tuneTypical Dose
Use preparation-specific dosing if trying a studied extract
Botanical
Echinacea
Echinacea spp.
Evidence TierCWADA NOT PROHIBITED
watchEffect Window
Cold-treatment studies focus on symptom days, while prevention studies track episodes over weeks to months.
check_circleCompliance
WADA NOT PROHIBITED
Overview
Clinical Summary
Some echinacea purpurea respiratory products may modestly reduce recurrent respiratory infections or cold duration, but product heterogeneity keeps the evidence messy and weaker than supplement marketing suggests.
Echinacea is one of the most studied immune botanicals, but it suffers badly from product heterogeneity. Reviews suggest at most a modest reduction in recurrent respiratory infections or cold duration with some preparations, including a newer pediatric meta-analysis. That remains a smaller and less reliable effect than the usual "boost immunity" framing.
Echinacea is often discussed as an immune modulator, but clinical effects depend heavily on species, plant part, extraction method, and dose.
Outcomes
What This Is Expected To Influence
Primary Outcomes
- Possible modest reduction in recurrent respiratory infections
Secondary Outcomes
- Possible small reduction in common-cold duration or severity with some preparations
Safety
Contraindications and Interactions
Contraindications
- Ragweed or Asteraceae allergy
Side effects
- GI upset
- Rash
Interactions
No entries provided
Avoid if
- You want a universally reliable cold-prevention product
Evidence
Study-level References
ech-SRC-001Cochrane review
Sourceopen_in_newKarsch-Völk M, et al. Echinacea for preventing and treating the common cold. Cochrane Database Syst Rev. 2014. doi:10.1002/14651858.CD000530.pub3. PMID:24554461.
Population: Adults and children from echinacea prevention and treatment trials for common cold.
Dose protocol: Mixed echinacea species and preparations
Key findings: Small possible benefit, but inconsistent and product dependent.
Notes: Best broad review.
Paper content
This review captures the central echinacea problem. Some preparations may help a little, but product heterogeneity makes the overall evidence inconsistent.
ech-SRC-002Meta-analysis
Sourceopen_in_newSchapowal A, et al. Echinacea reduces the risk of recurrent respiratory tract infections and complications: a meta-analysis of randomized controlled trials. Adv Ther. 2015. doi:10.1007/s12325-015-0194-4. PMID:25784510.
Population: Susceptible adults, children, and older persons from high-quality echinacea RCTs.
Dose protocol: Higher-quality placebo-controlled trials only
Key findings: Reduced recurrent respiratory infections and some complications.
Notes: Best favorable meta-analysis.
Paper content
This meta-analysis is the strongest favorable summary for echinacea. It suggests a modest reduction in recurrent respiratory infections and some complications.
ech-SRC-003Systematic review and meta-analysis of randomized controlled trials.
Sourceopen_in_newPham TP, Vu TMH, Doan PMK, Nguyen TTD, Bui TTT, Ha THL, Hoang TKQ, Taufani IP, Ha HA. Efficacy and safety of Echinacea purpurea in treating upper respiratory infections and complications of otitis media in children: systematic review and meta-analysis. Clin Nutr ESPEN. 2025;67:702-713. doi:10.1016/j.clnesp.2025.04.025. PMID:40311928.
Population: Children with upper respiratory tract infections and otitis media across 9 RCTs.
Dose protocol: Echinacea purpurea products in various forms across 9 RCTs in children
Key findings: Reduced URTI duration, episode incidence, and antibiotic use in children, with mild adverse events occurring more often than with placebo.
Notes: Most current pediatric-specific meta-analysis for echinacea in respiratory infections.
Paper content
This 2025 PRISMA-aligned meta-analysis pooled 9 pediatric RCTs with 3,169 total participants and found that Echinacea purpurea products modestly reduced upper-respiratory treatment duration, episode incidence, and antibiotic use. The pooled estimates were small rather than dramatic, with URTI duration improving by SMD -0.19 and episode risk by RR 0.81. Otitis-media episode incidence also fell, but treatment duration did not clearly change, which fits the more bacterial nature of OM. Mild adverse events were more common with echinacea than placebo. This record is useful because it quantifies the tradeoff directly: modest respiratory benefit, product heterogeneity, and a non-zero nuisance-adverse-event burden.